STAT1 and arthritic joint disease: These parameters most likely reflect concerns based on the published experience with JAKinibs in other scenarios, such as myelofibrosis, arthritis, and graft-versus-host disease (GVHD), as well as STAT1 GOF cases [8, 27, 28], FDA and EMA recommendations [19, 20].